Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq:PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it had made equity grants to two new employees under its 2021 Inducement Plan.
Related news for (PALI)
- MoBot alert highlights: NASDAQ: DFLI, NASDAQ: ASNS, NASDAQ: AREC, NASDAQ: PALI, NASDAQ: TSHA (10/02/25 04:00 PM)
- Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
- 24/7 Market News Snapshot 02 October, 2025 – Palisade Bio, Inc. Common Stock (NASDAQ:PALI)
- Breaking News: MoBot’s Latest Update as of 10/02/25 01:00 PM
- MoBot’s Stock Market Highlights – 10/02/25 08:00 AM